Changing the Way Anti-Cancer Drugs Are Developed
Cell Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel agents that seek to improve the safety and efficacy of existing standard-of-care cancer treatments, and those that may have unique, new mechanisms to kill cancer cells. We use genomic information to determine which tumors have the greatest chance of responding favorably to a specific drug candidate. This technology has the potential to change the way anti-cancer drugs are developed, by allowing investigators to pick the right drug for the right patient. It also has the potential to increase efficacy, lower development costs and approval time, and aim our best science at the highest-value markets.
Building Momentum
We are focused on gaining approvals for our two phase III product candidates, pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma, and OPAXIO in maintenance of ovarian cancer following complete remission after first-line treatment. We have one product in phase II clinical development, and other candidates in preclinical research. These products may address the therapeutic limitations of conventional cancer therapies.
 |
Corporate Profile
Investment Highlights
- Novel oncology portfolio spanning the entire spectrum of drug discovery, development, and commercialization
- Novel technology base to generate substantial licensing revenue streams
- Strong proprietary position through patents and orphan drug designation
- Proven merger and acquisition strategy
Key Statistics
- Ownership: Public
- Ticker Symbol: CTIC
- Initial Public Offering: March 1997
- Exchanges: NASDAQ, AMEX, PSEX, CBOE, MTA
- Collaborations: Novartis, PG-TXL Company, L.P., NerPharMa Srl, Translational Genomics Research Institute
The information provided on this site may contain Forward Looking Statements. For complete text of this statement, refer to Terms of Use. |
|
